A Phase 2 interventional study of BYM338 10 mg/kg and Placebo in Diabetes Mellitus, Type 2, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Diabetes Mellitus, Type 2 by Novartis — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Novartis.
Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, this one is the 86th largest by enrollment of the 121 interventional ones that give a count, is one of 3 that started in 2017, is one of 13 in phase 2, and was the 119th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 122 studies in Diabetes Mellitus, Type 2 by Novartis is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 23 · Phase 3 66 · Phase 4 30
First in 1992; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 183 across the 121 interventional studies. Of the 121 that completed or were terminated, 27 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
A non-confirmatory, randomized, subject and investigator blinded, placebo controlled, parallel-arm study, investigating a 48-week treatment period with i.v. bimagrumab 10 mg/kg in overweight and obese subjects with type 2 diabetes.
Participants were randomized and assigned to one of the following 2 treatment arms in a ratio of 1:1:
Arm 1: Bimagrumab 10 mg/kg up to maximum 1200 mg, every 4 weeks (12 doses) until week 44.
Arm 2: Placebo, every 4 weeks (12 doses) until week 44.
The study consisted of a screening baseline period of 3 weeks, treatment period of 48 weeks and then a follow-up period of 8 weeks.
Treatment period visits were scheduled every 4 weeks until week 44. Administration of bimagrumab or placebo was done via an i.v. infusion over 30 minutes followed by flushing for 15 minutes. Subjects were asked to return to the Investigator site for dosing approximately every 4 weeks during the treatment period. During those visits, subjects were evaluated for safety, tolerability, PK and efficacy. The treatment period ended approximately 4 weeks after the last dose administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
Drug: BYM338 10 mg/kg
Placebo, every 4 weeks until week 44 (12 doses)
Other: Placebo
Drug page: Bimagrumab
intravenous infusion every four weeks
Also known as: Bimagrumab
intravenous infusion every four weeks
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48
Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
Time frame: Baseline, Week 48
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24
Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
Time frame: Baseline, Week 24
Change From Baseline in HbA1c at Week 24 and 48
HbA1c reflects average glucose concentrations over the past 3 months and therefore provides a useful index of the glycemic control of bimagrumab over that time period. It is a standard endpoint used to assess the glycemic efficacy of any anti-diabetic medication. HbA1c is a key glycemic parameter which correlates with reduction of risk of diabetic complications.
Time frame: Baseline, Week 24, Week 48
The Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336
The trough observed analyte concentration (Ctrough) is the concentration that is just prior to the beginning of, or at the end of, a dosing interval (μg/mL).
Time frame: Day 84, 252, 336 at pre-dose only. Day 168, 308 at pre-dose and 45 mins post-dose
Maximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308
Cmax is the observed maximum plasma concentration following administration (μg/mL).
Time frame: Day 1, 168, 308 at pre-dose and 45 mins post-dose
Time to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308
Tmax is the time to reach peak or maximum concentration (h) after the drug administration.
Time frame: Day 1, 168, 308 at pre-dose and 45 mins post-dose
Change From Baseline in Body Mass Index (BMI)
Body Mass Index (BMI) was determined by height and weight measurements at week 24 and 48. A negative change from baseline indicates improvement. BMI was calculated as (Body weight (kg)/ \[Height (m)\]\^2)
Time frame: Baseline, Week 24, Week 48
Change From Baseline in Weight
Body weight was measured to the nearest 0.1 kilogram (kg) in indoor clothing without shoes. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 24, Week 48
Change From Baseline in Lean Body Mass (LBM) Measured by DXA
Lean body mass (LBM) is a part of body composition defined as the difference between total body weight and body fat weight. This means that it counts the mass of all organs except body fat, including bones, muscles, blood, skin, and everything else. Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
Time frame: Baseline, Week 24, Week 48
Change From Baseline in Waist Circumference
Waist circumference is the length in cm of the circumference to the nearest 0.1 cm at the level of the umbilicus with the subject in the upright position. A negative change indicates improvement.
Time frame: Baseline, Week 24, Week 52
Change From Baseline in Waist to Hip Ratio
Hip circumference was measured at the greatest protrusion of the buttocks. Combined with waist circumference, the waist-to-hip ratio was derived during data analysis.
Time frame: Baseline, Week 24, Week 52
Change From Baseline in Insulin Resistance (HOMA2-IR)
Blood samples were collected to analyze insulin resistance. The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). Higher numbers indicate higher insulin resistance. No established cutoffs are indicating impaired resistance. HOMA2-IR was calculated using an online calculator \[https://www.dtu.ox.ac.uk/homacalculator/\].
Time frame: Baseline. Week 12, Week 36
Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial
Describes the number of participants tested positive for anti-BYM338 antibodies after the start of bimagrumab (BYM338) treatment. A validated bridging enzyme-linked immunosorbent assay (ELISA) was used for the confirmation of the presence of anti-BYM338 antibodies in human serum.
Time frame: 392 days
The study was completed as planned.
| Milestone | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Started | 39 | 39 |
| Safety analysis set | 37 | 38 |
| Pharmacokinetics (pk) analysis set | 36 | 0 |
| Pharmacodynamics (pd) analysis set | 36 | 36 |
| Completed | 27 | 31 |
| Not completed | 12 | 8 |
| Withdrew: Withdrawal by subject | 7 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
| kg | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48 | -7.49 (-8.33 to -6.64) | -0.18 (-0.99 to 0.63) |
Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
| kg | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24 | -5.37 (-5.96 to -4.78) | -0.18 (-0.75 to 0.39) |
HbA1c reflects average glucose concentrations over the past 3 months and therefore provides a useful index of the glycemic control of bimagrumab over that time period. It is a standard endpoint used to assess the glycemic efficacy of any anti-diabetic medication. HbA1c is a key glycemic parameter which correlates with reduction of risk of diabetic complications.
| percentage change | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | -0.85 (-1.06 to -0.64) | 0.28 (0.08 to 0.48) |
| week 48 | -0.76 (-1.05 to -0.48) | 0.04 (-0.23 to 0.31) |
The trough observed analyte concentration (Ctrough) is the concentration that is just prior to the beginning of, or at the end of, a dosing interval (μg/mL).
| μg/mL | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Day 84 | 25.3 ± 6.20 | — |
| Day 168 | 27.5 ± 8.37 | — |
| Day 252 | 31.0 ± 11.2 | — |
| Day 308 | 29.9 ± 11.0 | — |
| Day 336 | 27.8 ± 10.9 | — |
Cmax is the observed maximum plasma concentration following administration (μg/mL).
| μg/mL | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Day 1 | 283 ± 32.0 | — |
| Day 168 | 292 ± 45.3 | — |
| Day 308 | 271 ± 31.1 | — |
Tmax is the time to reach peak or maximum concentration (h) after the drug administration.
| hr | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Day 1 | 0.750 (0.683 to 0.917) | — |
| Day 168 | 0.750 (0.750 to 1.05) | — |
| Day 308 | 0.750 (0.750 to 1.38) | — |
Body Mass Index (BMI) was determined by height and weight measurements at week 24 and 48. A negative change from baseline indicates improvement. BMI was calculated as (Body weight (kg)/ \[Height (m)\]\^2)
| Kg/m^2 | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | -1.50 (-1.77 to -1.23) | -0.17 (-0.43 to 0.10) |
| week 48 | -2.19 (-2.60 to -1.78) | -0.28 (-0.67 to 0.11) |
Body weight was measured to the nearest 0.1 kilogram (kg) in indoor clothing without shoes. A negative change from baseline indicates improvement.
| Kg | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | -3.99 (-4.79 to -3.19) | -0.57 (-1.34 to 0.21) |
| week 48 | -5.90 (-7.08 to -4.71) | -0.79 (-1.92 to 0.33) |
Lean body mass (LBM) is a part of body composition defined as the difference between total body weight and body fat weight. This means that it counts the mass of all organs except body fat, including bones, muscles, blood, skin, and everything else. Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.
| Kg | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | 1.72 (1.25 to 2.19) | 0.23 (-0.23 to 0.68) |
| week 48 | 1.70 (1.14 to 2.26) | -0.44 (-0.97 to 0.09) |
Waist circumference is the length in cm of the circumference to the nearest 0.1 cm at the level of the umbilicus with the subject in the upright position. A negative change indicates improvement.
| cm | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | -5.04 (-5.87 to -4.20) | -0.95 (-1.75 to -0.14) |
| week 52 | -9.00 (-10.3 to -7.68) | 0.45 (-0.79 to 1.69) |
Hip circumference was measured at the greatest protrusion of the buttocks. Combined with waist circumference, the waist-to-hip ratio was derived during data analysis.
| ratio | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 24 | -0.02 (-0.03 to -0.01) | -0.01 (-0.01 to 0.00) |
| week 52 | -0.05 (-0.06 to -0.04) | 0.01 (0.00 to 0.02) |
Blood samples were collected to analyze insulin resistance. The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). Higher numbers indicate higher insulin resistance. No established cutoffs are indicating impaired resistance. HOMA2-IR was calculated using an online calculator \[https://www.dtu.ox.ac.uk/homacalculator/\].
| Insulin Resistance (IR) Score | BYM338 10 mg/kg | Placebo |
|---|---|---|
| week 12 | 0.10 (-0.17 to 0.37) | 0.76 (0.50 to 1.02) |
| week 36 | -0.09 (-0.44 to 0.25) | 0.57 (0.24 to 0.90) |
Describes the number of participants tested positive for anti-BYM338 antibodies after the start of bimagrumab (BYM338) treatment. A validated bridging enzyme-linked immunosorbent assay (ELISA) was used for the confirmation of the presence of anti-BYM338 antibodies in human serum.
| Participants | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Confirmed with positive immunogenicity | 2 | 4 |
Collected over Adverse events were collected throughout the study for 56 weeks which includes the treatment period of 48 weeks and the follow-up period of 8 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338 10 mg/kg | 0/37 (0%) | 3/37 (8.1%) | 31/37 (83.8%) |
| Placebo | 0/38 (0%) | 3/38 (7.9%) | 31/38 (81.6%) |
| Event | BYM338 10 mg/kg | Placebo |
|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 1/37 | 0/38 |
| PancreatitisGastrointestinal disorders | 1/37 | 0/38 |
| PneumoniaInfections and infestations | 1/37 | 0/38 |
| Lipase increasedInvestigations | 1/37 | 0/38 |
| Acute coronary syndromeCardiac disorders | 0/37 | 1/38 |
| Acute myocardial infarctionCardiac disorders | 0/37 | 1/38 |
| Impaired gastric emptyingGastrointestinal disorders | 0/37 | 1/38 |
| CellulitisInfections and infestations | 0/37 | 1/38 |
| Thermal burnInjury, poisoning and procedural complications | 0/37 | 1/38 |
| Event | BYM338 10 mg/kg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/37 | 4/38 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 15/37 | 1/38 |
| Upper respiratory tract infectionInfections and infestations | 6/37 | 5/38 |
| HeadacheNervous system disorders | 0/37 | 5/38 |
| NauseaGastrointestinal disorders | 4/37 | 0/38 |
| Lipase increasedInvestigations | 4/37 | 2/38 |
| AnaemiaBlood and lymphatic system disorders | 3/37 | 0/38 |
| HypertensionVascular disorders | 3/37 | 1/38 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/37 | 3/38 |
| Abdominal painGastrointestinal disorders | 2/37 | 1/38 |
A total of 78 participants were randomized and were assigned to the respective treatment groups. Of the 78 participants, 3 withdrew from the study prior to dosing due to subject/physician decision. The remaining 75 participants underwent baseline assessments and treatment analysis.
| Age, Continuous(Years) | BYM338 10 mg/kg | Placebo | Total |
|---|---|---|---|
| Mean | 60.7 ± 7.50 | 60.2 ± 8.02 | 60.4 ± 7.72 |
| Sex: Female, Male(Participants) | BYM338 10 mg/kg | Placebo | Total |
|---|---|---|---|
| Female | 23 | 12 | 35 |
| Male | 14 | 26 | 40 |
| Race/Ethnicity, Customized(Participants) | BYM338 10 mg/kg | Placebo | Total |
|---|---|---|---|
| Race — Black Or African American | 6 | 9 | 15 |
| Race — Other | 1 | 0 | 1 |
| Race — White | 30 | 27 | 57 |
| Race — Asian | 0 | 1 | 1 |
| Race — Unknown | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | BYM338 10 mg/kg | Placebo | Total |
|---|---|---|---|
| Ethnicity — Hispanic Or Latino | 27 | 25 | 52 |
| Ethnicity — Not Hispanic Or Latino | 9 | 12 | 21 |
| Ethnicity — Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2017 to primary completion in Mar 2019, 25 months.
Results were first posted in Jun 2020, 1 year 2 months after primary completion. A results delay was requested in Aug 2019.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 25 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab